IP Library Granted Patent US 6,927,061
Granted Patent B2
US 6,927,061 · App. 10/445,179 · Granted Aug 9, 2005

Human ovarian mesothelial cells and methods of isolation and uses thereof

Assignee: Raven Biotechnologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,927,061
App. No.
10/445,179
Granted
Aug 9, 2005
Kind
B2
Abstract

The invention discloses a substantially pure population of human ovarian mesothelial cells and methods of isolating and culturing the ovarian mesothelial cells. By carefully manipulating the microenvironment of the ovarian mesothelial cells, multiple passages are attainable wherein the ovarian mesothelial cells are capable of becoming ovary surface epithelial cells or granulosa cells. In addition, several methods of use of human ovarian mesothelial cells are disclosed herein.

Claims (12)

1. A method of isolating a substantially pure population of ovarian mesothelial cells, comprising:

(a) microdissecting a source of human fetal ovarian mesothelial cells;

(b) placing the source of ovarian mesothelial cells in nutrient media under culture conditions sufficient to sustain life of said ovarian mesothelial cells and wherein the nutrient media contains nutrients consisting of insulin, transferrin, epidermal growth factor, α-tocopherol, recombinant human heregulin β1, bovine serum albumin, and aprotinin;

(c) maintaining suitable culture conditions sufficient to allow the migration of ovarian mesothelial cells from the source of ovarian mesothelial cells into the nutrient media;

(d) maintaining suitable culture conditions sufficient to allow ovarian mesothelial cells to form aggregate or monolayer formations; and

(e) subculturing said aggregate or monolayer formations to obtain a substantially pure population of ovarian mesothelial cells.

2. A method of isolating a substantially pure population of ovarian mesothelial cells which have a pluripotent capacity to differentiate into ovary surface epithelial cells or granulosa cells, comprising the steps of:

(a) microdissecting a source of human fetal ovarian mesothelial cells;

(b) placing the source of ovarian mesothelial cells in nutrient media under culture conditions sufficient to sustain life of said ovarian mesothelial cells and wherein the nutrient media contains nutrients consisting of insulin, transferrin, epidermal growth factor, α-tocopherol, recombinant human heregulin β1, bovine serum albumin, and aprotinin;

(c) maintaining suitable culture conditions sufficient to allow the migration of ovarian mesothelial cells from the source of ovarian mesothelial cells into the nutrient media;

(d) maintaining suitable culture conditions sufficient to allow ovarian mesothelial cells to form aggregate or monolayer formations; and

(e) subculturing said aggregate or monolayer formations to obtain an isolated, substantially pure population of ovarian mesothelial cells which have a pluripotent capacity to differentiate into ovary surface epithelial cells or granulosa cells.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2014
From: MACROGENICS WEST, INC.
To: MACROGENICS, INC.
Reel/Frame 034630/0402 →
SECURITY AGREEMENT Recorded Jan 12, 2011
From: DIADEXUS, INC. (FORMERLY VAXGEN, INC.)
To: RAVEN BIOTECHNOLOGIES, INC.
Reel/Frame 025622/0237 →
SECURITY AGREEMENT Recorded Jun 13, 2008
From: RAVEN BIOTECHNOLOGIES, INC.
To: VAXGEN, INC.
Reel/Frame 021096/0008 →
Continuity (2)
Division 0954565900 · Apr 10, 2000
Related Publication 20030207449A1 · Nov 6, 2003